

Oligometastatic non-small-cell lung cancer. Current management

Alicia Román-Jobacho, María Hernández-Miguel, María Jesús García-Anaya, Jaime Gómez-Millán, JA Medina-Carmona, Ana Otero-Romero

Corresponding author

Ana Otero-Romero

Department of Radiation Oncology, Hospital Virgen de la Victoria. Campus Teatinos s/n. 29010 Málaga. Spain

Handling editor:

Michal Heger

Department of Pharmaceutics, Utrecht University, the Netherlands

Department of Pharmaceutics, Jiaying University Medical College, Zhejiang, China

Review timeline:

Received: 30 September, 2020
Editorial decision: 19 November, 2020
Revision received: 17 December, 2020
Editorial decision: 18 March, 2021
Revision received: 15 April, 2021
Editorial decision: 15 April, 2021
Published online: 27 May, 2021

1st Editorial decision
19-Nov-2020

Ref.: Ms. No. JCTRes-D-20-00108
Oligometastatic non-small-cell-lung-cancer: current management
Journal of Clinical and Translational Research

Dear Dr OTERO-ROMERO,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript. If you are prepared to undertake the work required, I would be pleased to reconsider my decision.

For your guidance, reviewers' comments are appended below.

If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is being raised when you submit the revised manuscript. Also, please ensure that the track changes function is switched on when implementing the revisions. This enables the reviewers to rapidly verify all changes made.

Your revision is due by Dec 19, 2020.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author.

You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Reviewers' comments:

Reviewer #1: This paper provides a thorough overview of the clinical literature on the topic of radiation treatment for oligometastatic non-small cell lung cancer. A few revisions are recommended to the authors in order to the strengthen the manuscript.

1. Unfortunately, there are significant grammatical errors scattered throughout the paper which are too numerous to list which need fixed.
2. I do think the section on treatment of brain oligometastasis can be shortened. I do not think many patients will be considered for whole brain radiation therapy in this cohort so the summary of whole brain radiation trials may not be necessary.
3. I do think the paper could be enriched by a few paragraphs on the role of radiation in the treatment of patients with oligoprogression who are on immune checkpoint inhibitors. This is an increasing common clinical scenario in NSCLC. It may be worth mentioning the STOP trial or other data /studies that evaluate SBRT for oligoprogression on checkpoint inhibitors <https://clinicaltrials.gov/ct2/show/NCT03808662>.
4. Also the hypothesis of synergism of lung SBRT with immune checkpoint inhibitors may be of interest to the journal's audience. Studies on this topic include the PEMBRO-RT study (doi:10.1001/jamaoncol.2019.1478) and this pooled analysis of 2 studies ([https://doi.org/10.1016/S2213-2600\(20\)30391-X](https://doi.org/10.1016/S2213-2600(20)30391-X)).

Authors' response

Dear reviewers,

Thank you for your revision,

We have revised the manuscript following your comments.

1. We have corrected the grammatical errors.
2. We have shortened the section on treatment of brain oligometastasis by removing the resume of the whole brain radiation therapy trials.

3. We have added a new section on SBRT and immune checkpoint inhibitors.

I hope these corrections have improved your view of the article.

2nd Editorial decision
18-Mar-2021

Ref.: Ms. No. JCTRes-D-20-00108R1
Oligometastatic non-small-cell-lung-cancer: current management
Journal of Clinical and Translational Research

Dear author(s),

Reviewers have submitted their critical appraisal of your paper. The reviewers' comments are appended below. Based on their comments and evaluation by the editorial board, your work was FOUND SUITABLE FOR PUBLICATION AFTER MINOR REVISION.

If you decide to revise the work, please itemize the reviewers' comments and provide a point-by-point response to every comment. An exemplary rebuttal letter can be found on at <http://www.jctres.com/en/author-guidelines/> under "Manuscript preparation." Also, please use the track changes function in the original document so that the reviewers can easily verify your responses.

Your revision is due by Apr 17, 2021.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Reviewers' comments:

Dear authors,

Firstly we must apologize to you for the delay in receiving the reviewer report. The original reviewer was not responding to his assignment, and after two reminders we terminated his assignment and evaluated your manuscript ourselves.

Based on your modifications, we deem the manuscript eligible for publication as you have properly addressed all of the reviewer's concerns. However, your manuscript is still replete with grammar, spelling, and syntax errors. As explained in our author guidelines, manuscripts must conform to academic English standards before we can publish them. Please consult with a native speaker to proofread the text, or otherwise consult the journal's board for help. We

have experts who can assist for a fee.

Thank you,

Michal Heger
Editor

3rd Editorial decision

15-Apr-2021

Ref.: Ms. No. JCTRes-D-20-00108R2

Oligometastatic non-small-cell-lung-cancer: current management

Journal of Clinical and Translational Research

Dear authors,

I am pleased to inform you that your manuscript has been accepted for publication in the Journal of Clinical and Translational Research.

You will receive the proofs of your article shortly, which we kindly ask you to thoroughly review for any errors.

Thank you for submitting your work to JCTR.

Kindest regards,

Michal Heger
Editor-in-Chief
Journal of Clinical and Translational Research

Comments from the editors and reviewers: